Ernexa Therapeutics Inc.

ERNA

$4.41

-2.64%

2026-09-04 12:49:37 EDT-$0.12

Healthcare

Biotechnology

NASDAQ

Active Trading

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced ...

Fundamental Analysis of ERNA

Key Strengths

Lead pipeline is differentiated by cytokine-engineered iMSC design (e.g., ERNA-101 releasing IL-7/IL-15; ERNA-102 releasing IL-10), potentially enabling immune modulation tailored to tumor/autoimmune settings.

Preclinical efficacy signals referenced by the market (reports of strong outcomes in ovarian cancer models) provide high-upside scientific optionality.

Risk Factors

Preclinical-stage execution risk: ERNA-101/ERNA-102 efficacy and safety in animals may fail to translate to humans, which is common in biotech.

Financing and dilution risk: negative operating cash flow and negative free cash flow suggest ongoing capital needs; financing could dilute shareholders.

Profitability

Net Margin0.00%

Operating Margin0.00%

Valuation

P/E Ratio-0.23x

Current Ratio2.01

Efficiency

ROE-305.85%

ROA-194.09%

Fundamental Analysis of ERNA

Ernexa Therapeutics Inc. (NASDAQ: ERNA) is a preclinical biotechnology company developing engineered induced mesenchymal stem cell (iMSC) therapies for solid tumors and autoimmune diseases. The company is in an early stage of value creation: its lead programs—ERNA-101 (iMSC engineered to release IL-7 and IL-15 for ovarian cancer) and ERNA-102 (iMSC engineered to secrete IL-10 for rheumatoid arthritis)—remain preclinical, where outcomes are highly uncertain and typically require additional regulatory, manufacturing, and clinical validation before meaningful commercial potential. From a fundamentals perspective, the financial profile is consistent with an R&D-intensive, pre-revenue model. The provided TTM snapshot shows no meaningful profitability measures (margins effectively at 0 and net profit margin shown as 0), negative returns (ROA and ROE are materially negative), and negative operating/FCF-based yields. Free cash flow and operating cash flow are negative, indicating the company likely depends on capital raises and/or financing arrangements to fund development activities. Balance-sheet liquidity appears supportive in the near term: current ratio (2.01) and quick ratio (2.01) are above 1, and reported debt-to-equity is low (0.109), suggesting limited leverage risk. However, several coverage and solvency indicators are weak/negative (e.g., interest coverage is negative, solvency ratio negative), which underscores that operating income is not yet able to service financing needs. Valuation metrics in the snapshot are not reliable in typical earnings-based terms because earnings are negative (P/E is negative; price-to-sales is shown as 0 due to TTM revenue data not being present/valid in the source). The market capitalization provided (~$1.53M) is extremely small, and the stock’s high beta (2.56) and wide trading range reflect pronounced volatility. While preclinical data (including references to strong survival/tumor clearance in models) can create upside optionality, it does not reduce the key fundamental risks: clinical translation risk, regulatory/manufacturing scale-up risk, financing risk for a pre-revenue company, and potential dilution. Overall, ERNA is best characterized as a high-risk, catalyst-driven development-stage biotech rather than a fundamentally stable cash-flow compounder. For long-term investors, the thesis depends on (1) successful IND-enabling packages and clinical starts, (2) demonstrable efficacy/safety signals in humans, and (3) adequate runway through planned financing without excessive dilution.

Key Strengths of ERNA

Lead pipeline is differentiated by cytokine-engineered iMSC design (e.g., ERNA-101 releasing IL-7/IL-15; ERNA-102 releasing IL-10), potentially enabling immune modulation tailored to tumor/autoimmune settings.
Preclinical efficacy signals referenced by the market (reports of strong outcomes in ovarian cancer models) provide high-upside scientific optionality.
Liquidity appears adequate on paper (current ratio and quick ratio ~2.01), which can support continued R&D while advancing toward clinical development.
Low balance-sheet leverage (debt-to-equity ~0.109) reduces immediate default/solvency pressure versus highly levered biotech peers.
Clear therapeutic focus areas (solid tumors and autoimmune diseases) can streamline development strategy and trial design if early evidence holds.

Risk Factors of ERNA

Preclinical-stage execution risk: ERNA-101/ERNA-102 efficacy and safety in animals may fail to translate to humans, which is common in biotech.
Financing and dilution risk: negative operating cash flow and negative free cash flow suggest ongoing capital needs; financing could dilute shareholders.
Unreliable/immature fundamentals: margins, profitability, and cash-flow yields are negative/near-zero in the provided snapshot, limiting confidence in valuation.
Regulatory and manufacturing risk: cell therapy manufacturing consistency (CMC) and scale-up are challenging; delays or quality issues can impair timelines and funding prospects.
Clinical/commercial uncertainty for niche immuno-cell approaches: even if efficacy is shown, competitive differentiation and endpoint selection may be difficult.
High volatility and high beta (beta ~2.56) increases downside risk and makes returns highly sensitive to near-term catalysts and capital markets.

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$1.39M

-0.2x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin0.00%

Net Profit Margin0.00%

Debt/Equity Ratio0.11

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of ERNA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of ERNA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of ERNA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	2.010	—	—	Flat
Quick Ratio	—	2.010	—	—	Flat
Debt / Equity	—	0.109	—	—	Flat

Valuation of ERNA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-0.49x	—	—	Flat
P/B	—	2.46x	—	—	Flat

Supply Chain of ERNA

RELATIONS

Upstream

Factor Bioscience Inc.Cellipont BioservicesLineage Cell Therapeutics Inc.NYSE:LCTX Thermo Fisher Scientific Inc.NYSE:TMOLonza Group AGSWX:LONNSartorius AGETR:SRT3

Downstream

Ovarian Cancer Patient Population (Target for ERNA-101)Autoimmune Disease Patient Population (Target for ERNA-201)Prospective Big Pharma/Biotech Licensing Partners

Proxies

Fate Therapeutics Inc.NASDAQ:FATE Century Therapeutics Inc.NASDAQ:IPSC Lineage Cell Therapeutics Inc.NYSE:LCTX Mesoblast LimitedNASDAQ:MESO

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer